

## PERSONAL INFORMATION

## Angela Zampella



University of Naples "Federico II"  
Department of Pharmacy  
Via D. Montesano 49, 80131, Naples, Italy

+39 081678525

angela.zampella@unina.it

<http://orcid.org/0000-0002-6170-279X>  
<https://www.iris.unina.it/simple-search?query=zampella#.VOK8buRoDdM>  
[https://www.researchgate.net/profile/Angela\\_Zampella/contributions](https://www.researchgate.net/profile/Angela_Zampella/contributions)  
[https://scholar.google.it/citations?user=\\_WvzxcwAAAAJ&hl=it](https://scholar.google.it/citations?user=_WvzxcwAAAAJ&hl=it)

Sex Female | Date of birth 13/09/1967 | Nationality Italian

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input checked="" type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist
<input type="checkbox"/> Mid-Management Level	<input type="checkbox"/> Associate Professor	<input type="checkbox"/> Level III Researcher and Technologist
<input type="checkbox"/> Employee / worker level	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator	<input type="checkbox"/> Researcher and Technologist of IV, V, VI and VII level / Technical collaborator

## WORK EXPERIENCE

Since December 2018

### Head of the Department

Department of Pharmacy, University of Naples "Federico II"

Since October 2020

**Board Member of Ceinge -Biotechnologie Avanzate** operating in the field of molecular biology and advanced biotechnology applied to Human Health, s an excellence in Italy and abroad for the Research and Diagnostics of genetic diseases (hereditary and acquired).

December 2016- now

### Full Professor of Organic Chemistry

Department of Pharmacy, University of Naples "Federico II"

2013- now

### Member of the board for PhD programme in Pharmaceutical Science

Department of Pharmacy, University of Naples "Federico II"

November 2002-December 2016

### Associate Professor of Organic Chemistry

Department of Pharmacy, University of Naples "Federico II"

September 1998- Ottobre 2002

### Researcher of Organic Chemistry

Department of Pharmacy, University of Naples "Federico II"

## EDUCATION AND TRAINING

1995

### PhD in "Sostanze Naturali Farmacologicamente attive"

Department of Pharmacy University of Naples "Federico II"

May-October 1994

### Visiting Researcher

Institut de Chimie des Substances Naturelles- CNRS- Gif sur Yvette (France)

## PERSONAL SKILLS

### Mother tongue

Italian

### Other language

English and French (advanced)

### Organisational skills and competences

Head of the Department of Pharmacy, University of Naples, Federico II, recognized as Department of Excellence (MUR 2018-2022 and 2023-2027). Angela Zampella is leader of a large research group including permanent staff, PhD and post-docs, working on the isolation from natural sources, design, synthesis and pharmacological profiling of new drugs in metabolic disorders, with the research activity results reported in 7 family patents (see below), one of which licensed worldwide. Notably, one of the discovered molecules has recently entered in Phase I clinical trial (ClinicalTrials.gov Identifier: NCT05203367).

## WORK ACTIVITIES

### Awards

Selection of the contribution "BAR502, a dual FXR and GPBAR1 agonist, reverses steatosis and fibrosis in rodent model of NASH by modulating autophagic genes", in the International Conferences DDW (Digestive Disease Week) San Diego, May 21-24, 2016.

### Editorial activity

Referee for J. Med. Chem, Steroids, Marine Drugs, Org. Lett., Bioorg. Med. Chem., Scientific Reports, Nature Communication, PLoS One, Tetrahedron, J. Org. Chem, Journal of Immunology

### Grants

- Leader for a Pharma collaborating project (2015 to date) in the development of new drugs in liver fibrosis (about 500.000 €).

-PI and Coordinator for Federico II of "National Center for Gene Therapy and Drugs based on RNA Technology" PNRR MUR – M4C2 – Project number: E63C22000940007 (27 M€)  
 -Unit coordinator (Federico II) for "Infrastructure for precision medicine in oncology (PREMIO)", [26/11/2018 – Current] (2.7 M€).  
 -Department of Excellence "Project TRAVEL" 2023-2027 (9,2 M€ MUR)  
 -Unit Coordinator (Federico II) of Regione Campania project "Fighting Cancer resistance: Multidisciplinary, integrated Platform for a technological Innovative Approach to Oncotherapies (Campania Oncotherapies)", Project N. B61G18000470007 [01/01/2018 – Current] (660.000 €);  
 -Department of Excellence "Project Health" 2018-2022 (9,3 M€ MUR + 4 M€ cofound)  
 -Head of RU for the project PRIN2017: Bile acids activated receptors and liver metabolism: discovery and development of novel therapeutic targets in the treatment of steato-hepatitis (NASH). Funded by MUR.

#### Patents

- Sterols in the treatment and/or prevention of sars-cov-2 infection. PCT International patent application (PCT/IB2021/054142, filed 14.05.2021)  
 - 6-Substituted, 22-cyano hyodeoxycholic analogues and uses thereof. PCT International patent application (PCT/IB2020/061695, filed 09.12.2020)  
 - Isoxazoles as FXR receptor agonists and their preparation. PCT International patent application PCT/IB2019/056114, filed 17.07.2019  
 - Preparation of oxadiazoles as FXR receptor antagonists. PCT International patent application PCT/IB2019/054238, filed 22.05.2019, licensed as IT201800005598A1 (22.11.2019)  
 - Synthesis of hyodeoxycholic acid derivatives for pharmaceutical use. PCT International patent application PCT/IB2017/053959, filed 30.06.2017, licensed as IT201600068742A1 (01.01.2018)  
 - Derivati chimici del colano per l'uso nel trattamento e/o nella prevenzione delle malattie mediate dai recettori FXR e TGR5/GP-BAR1. Patent application ITUA20161663A, filed 15.03.2016, licensed as ITUA20161663A1 (15.09.2017)  
 - Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases, PCT International patent application (PCT/EP2015/061802, filed 28.05.2015), licensed as AU2015265893B2; CA2948585A1; CN106661079B; CN110003301A; DK3149019T3; EA032820B1; EA201692316A1; EP3149019A1; EP3149019B1; EP3626725A1; ES2768718T3; HRP20200225T1; HUE048351T2; JP2017516856A; JP6820253B2; KR20170008767A; LT3149019T; MA39881B1; MX2016015724A; PH12016502327A1; PL3149019T3; PT3149019T; RS59910B1; SG10201809362RA; SG11201609403UA; SI3149019T1; US10407462B2; US11117926B2; US2017190731A1; US2019352328A1; WO2015181275A8

#### ADDITIONAL INFORMATION

Publications Author and co-author of 165 scientific products; From Scopus: H-index: 41; total citations: 5008.

#### The most relevant publications

- Zampella A. et al. Combinatorial targeting of G-protein-coupled bile acid receptor 1 and cysteinyl leukotriene receptor 1 reveals a mechanistic role for bile acids and leukotrienes in drug-induced liver injury. *Hepatology*, 2022
- Zampella A. et al. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. 2022, 36(1), e22060
- Zampella A. et al. Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1. *Journal of Medicinal Chemistry*, 2021, 64(22), pp. 16512-16529
- Zampella A. et al. Bile acids and their receptors in metabolic disorders. *Progress in Lipid Research* 2021, 82,101094
- Zampella A. et al Identification of cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1. *Biochemical Pharmacology* 2020, 177, 113987
- Zampella A. et al Bile acids activated receptors regulate innate immunity. *Frontiers in Immunology* 2018,1853
- Zampella A. et al. The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of gpbar1 rescues mice from murine colitis . *Journal of Immunology* 2017, 199(2), pp. 718-733

Naples March 20, 2023

